Clinical considerations for older patients with glioblastoma Journal Article
| Authors: | Abrey, L. E.; Finnegan, T.; Iwamoto, F. M. |
| Article Title: | Clinical considerations for older patients with glioblastoma |
| Abstract: | The current treatment modalities for GBM include a combination of surgical resection, RT, and chemotherapy. As patients age, they are less likely to receive aggressive forms of therapy. The disparity in treatment stems from a variety of sources. Older patients are more likely to have multiple chronic medical conditions and may be taking multiple prescription medications, both of which can adversely influence the safety of therapies for GBM. However, multiple studies have shown that older patients with GBM who are in generally good health can derive an overall survival and PFS benefit from aggressive therapy. In the development of a treatment plan for older adults with GBM, the general level of health is more predictive of treatment outcome than age. Doctor-patient communication is an aspect of delivering optimal care that is often overlooked. Patients vary regarding how much information they want about their condition and how involved they want to be in developing a treatment plan. Data have also shown that oncology patients have an interest in clinical trial participation if it is offered by the treating physician. Despite the dearth of clinical trials that allow for the inclusion of older adults, there are clinical trials currently under way in GBM that include older patients. It is important that the clinician understands the patient's preferences. The results of future GBM studies would benefit greatly from the inclusion of older patients, because many older patients are interested in clinical trial participation, and GBM occurs most frequently in this age group. ©2010 Millennium Medical Publishing, Inc. All rights reserved. |
| Keywords: | cancer survival; treatment outcome; aged; unclassified drug; gene mutation; methylation; gene deletion; clinical trial; constipation; fatigue; neutropenia; review; bevacizumab; cancer growth; hypertension; monotherapy; multimodality cancer therapy; side effect; radiation dose; temozolomide; neurotoxicity; nuclear magnetic resonance imaging; brain tumor; glioma; colorectal cancer; cytoreductive surgery; medical decision making; gene overexpression; progression free survival; infection; bone marrow suppression; blood toxicity; nausea; thrombocytopenia; vomiting; propofol; sedation; epidermal growth factor receptor; genetic association; dexamethasone; vincristine; pneumocystis pneumonia; tumor biopsy; microsurgery; protein p53; lomustine; procarbazine; hyperglycemia; lymphocytopenia; postoperative complication; doctor patient relation; medical information; drug mechanism; thromboembolism; adjuvant chemotherapy; thrombosis; glioblastoma; comorbidity; cediranib; glucocorticoid; caregiver; craniotomy; seizure; weakness; bone mass; heterozygosity loss; methylated dna protein cysteine methyltransferase; anticonvulsive agent; brain mapping; gamma glutamyltransferase; analgesia; astrocytoma; gliosarcoma; mental health; inappropriate vasopressin secretion; bone necrosis; social psychology; brain edema; polypharmacy; fentanyl; dexmedetomidine; aminolevulinic acid; cyclin dependent kinase 2; cyclin dependent kinase 2a; remifentanil; behavior change; neuronavigation; urosepsis; wakefulness |
| Journal Title: | Clinical Advances in Hematology & Oncology |
| Volume: | 8 |
| Issue: | 1 Suppl. |
| ISSN: | 1543-0790 |
| Publisher: | Millennium Medical Publishing, Inc |
| Date Published: | 2010-01-01 |
| Start Page: | 3 |
| End Page: | 14 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 20237435 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 20 April 2011" - "Source: Scopus" |
